ArticleOncogene2007
Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53.
Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 97 citations in OpenAlex.
- Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer.Genetic testing and molecular biomarkers · 2012Trial
- Evaluation of Stathmin Expression in Different Oral Squamous Lesions: A Retrospective Cross-Sectional Study.International journal of dentistry · 2026Article
- Identification of two heterogeneous subtypes of hepatocellular carcinoma with distinct pathway activities and clinical outcomes based on gene set variation analysis.Frontiers in genetics · 2024Article
- Knockdown of MRPL35 promotes cell apoptosis and inhibits cell proliferation in non-small-cell lung cancer.BMC pulmonary medicine · 2023Article
- Expression of stathmin in asbestos-like fibers-induced mesothelioma: A preliminary report.Histology and histopathology · 2023Article
- Mining the plasma-proteome associated genes in patients with gastro-esophageal cancers for biomarker discovery.Scientific reports · 2021Article
- TMT-Based Quantitative Proteomic Analysis Reveals the Effect of Bone Marrow Derived Mesenchymal Stem Cell on Hair Follicle Regeneration.Frontiers in pharmacology · 2021Article
- Amentoflavone triggers cell cycle G2/M arrest by interfering with microtubule dynamics and inducing DNA damage in SKOV3 cells.Oncology letters · 2020Article
- Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma.Acta neuropathologica communications · 2020Article
- Stathmin 1 Induces Murine Hepatocyte Proliferation and Increased Liver Mass.Hepatology communications · 2020Article
- The toxic effect of cytostatics on primary cilia frequency and multiciliation.Journal of cellular and molecular medicine · 2019Article
- Stathmin inhibits proliferation and differentiation of dental pulp stem cells via sonic hedgehog/Gli.Journal of cellular and molecular medicine · 2018Article
- Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma.Journal of experimental & clinical cancer research : CR · 2017Article
- Siva 1 inhibits proliferation, migration and invasion by phosphorylating Stathmin in ovarian cancer cells.Oncology letters · 2017Article
- Stathmin 1 promotes the proliferation and malignant transformation of pancreatic intraductal papillary mucinous neoplasms.Oncology letters · 2017Article
- Effect of the p53-tristetraprolin-stathmin-1 pathway on trophoblasts at maternal-fetal interface.PloS one · 2017Article
- The cytotoxic effect of memantine and its effect on cytoskeletal proteins expression in metastatic breast cancer cell line.Iranian journal of basic medical sciences · 2017Article
- Downregulation of stathmin 1 in human gallbladder carcinoma inhibits tumor growth in vitro and in vivo.Scientific reports · 2016Article
- Enhancement of Chemosensitivity by Stathmin-1 Silencing in Gastric Cancer Cells In Situ and In Vivo.Oncology research · 2016Article
- Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cancers harboring dominant-negative p53 mutations are often aggressive and difficult to treat. Direct attempts to restore wild-type p53 function have produced little clinical benefit. We investigated whether targeting a p53-target gene could induce certain tumor-suppressor characteristics. We found that inhibition of stathmin, a microtubule regulator that can be transcriptionally repressed by wild-type p53, restored certain wild-type functions to cancer cells with mutant p53. Silencing of stathmin by small interfering RNA (siRNA) in mutant p53 cell lines lowered expression to that observed following activation of wild-type p53 by DNA damage in wild-type p53 cell lines. siRNA-induced repression of stathmin decreased cell proliferation, viability and clonogenicity in mutant p53 cell lines. Furthermore, knockdown of stathmin partially restored cell-cycle regulation and activation of apoptosis. Therefore, targeting stathmin, a gene product that is overexpressed in the presence of mutant p53, may represent a novel approach to treating cancers with aberrant p53 function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.